Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Scheduled to Post Quarterly Earnings on Wednesday
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, August 2nd. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.
Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. During the same period in the previous year, the firm earned ($0.13) earnings per share. On average, analysts expect Achillion Pharmaceuticals to post $-0.64 EPS for the current fiscal year and $-0.09 EPS for the next fiscal year.
Shares of Achillion Pharmaceuticals, Inc. (NASDAQ ACHN) opened at 4.22 on Wednesday. Achillion Pharmaceuticals, Inc. has a one year low of $3.15 and a one year high of $9.49. The firm has a 50-day moving average price of $4.45 and a 200 day moving average price of $4.13. The stock’s market capitalization is $576.97 million.
A number of equities analysts have recently weighed in on ACHN shares. Robert W. Baird boosted their price target on Achillion Pharmaceuticals from $5.00 to $10.00 and gave the stock an “outperform” rating in a report on Monday, April 24th. Leerink Swann raised Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $4.00 to $6.00 in a report on Thursday, May 18th. Jefferies Group LLC reissued a “hold” rating on shares of Achillion Pharmaceuticals in a report on Wednesday, April 26th. Maxim Group cut their price target on Achillion Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday, April 25th. Finally, BidaskClub raised Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $8.75.
TRADEMARK VIOLATION NOTICE: This piece was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/26/achillion-pharmaceuticals-inc-nasdaqachn-scheduled-to-post-quarterly-earnings-on-wednesday.html.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.